South Korean Company Announces Development of Oral GLP-1 Treatment

Stock.adobe.com

Anti-obesity medications (AOMs) rose in prominence in the last year thanks to the success of GLP-1 medications like Ozempic and Wegovy. Thanks to the ability of these drugs to reduce appetite and increase feelings of being satiated, they have become popular choices for patients looking to manage their weight. These drugs are generally administered through an injection, which may be a factor that prevents some patients from using them.

Dx&Vx is a South Korean company working on an oral GLP-1 obesity treatment.¹ Using AI-based technology, the company has identified multiple drug candidates that it believes can work as oral GLP-1 treatments.

The company is still in the early stages of development for these medications, however. According to a press release, it is still in the early research phase and filing drug patents. The company plans on using its research results to obtain research funding investments, along with early licensing offers, and opportunities for joint global clinical trials.

In a press release, a spokesperson for the company said, “The current research results and development progress are important achievements that prove the possibility of an oral obesity treatment with the safe and powerful effects that the market needs. We will continue to develop innovative treatments through continuous research and development, aiming for early commercialization and showcasing our results at international academic conferences."

New drug candidate identification is not the only way that Dx&Vx is using AI-based technology. In December 2023, the company announced that it was developing a data platform for bio-healthcare using AI-technology provided by LG CNS.²

The two companies had entered into an agreement to jointly develop the platform and is the first instance of LG CNS working with a domestic pharma-bio company. According to Dx&Vx, the platform is designed to identify and discover new potential biomarkers for various cancers, rare diseases, and other conditions.

In a press release, a spokesperson for Dx&Vx said, “Currently, we are implementing artificial intelligence (AI) algorithm in new drug development projects to increase the possibility of success in new drugs development, and we are expanding collaboration with domestic and foreign IT companies to expand related services. This joint development will be the starting point for Dx&Vx to grow into a global integrated biomedical big data-based bio-healthcare personalized precision medicine solution provider.”

Sources

DX&VX is on Track and Accelerating the Development of Oral Obesity Treatment. Dx&Vx. July 18, 2024. https://www.prnewswire.com/news-releases/dxvx-is-on-track-and-accelerating-the-development-of-oral-obesity-treatment-302200601.html

Dx&Vx Co-Develops a Bio-Healthcare Big Data Platform with LG CNS. Dx&Vx. December 20, 2023. Accessed July 18, 2024. https://www.prnewswire.com/news-releases/dxvx-co-develops-a-bio-healthcare-big-data-platform-with-lg-cns-302019872.html